Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.63 1.44 (1.6%) as of 4:30 Fri 4/19


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.70(B)
Last Volume: 1,778,607 Avg Vol: 1,398,026
52 Week Range: $76.22 - $99
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 139,229 182,993 316,353 638,922
Total Sell Value $12,316,080 $16,513,389 $28,948,007 $60,375,372
Total People Sold 5 5 6 8
Total Sell Transactions 11 15 24 57
End Date 2024-01-25 2023-10-24 2023-04-25 2022-04-25

   
Records found: 2549
  Page 1 of 102  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Bienaime Jean Jacques Director   –       •      –    2024-04-12 4 AS $91.26 $1,825,200 D/D (20,000) 474,994 -4%     
   Bienaime Jean Jacques Director   –       •      –    2024-04-12 4 OE $63.10 $1,262,000 D/D 20,000 494,994     -
   Bienaime Jean Jacques Director   –       •      –    2024-04-11 4 AS $90.99 $1,819,800 D/D (20,000) 474,994 -3%     
   Bienaime Jean Jacques Director   –       •      –    2024-04-11 4 OE $63.10 $1,262,000 D/D 20,000 494,994     -
   Burkhart Erin GVP, Chief Accounting Officer   •       –      –    2024-04-10 4 AS $90.00 $205,740 D/D (2,286) 16,156 -2%     
   Davis George Eric EVP, Chief Legal Officer   •       –      –    2024-03-28 4 AS $88.34 $2,173,341 D/D (24,602) 55,856 1%     
   Slamon Dennis Director   –       •      –    2024-03-18 4 D $83.81 $797,033 D/D (9,510) 31,299     -
   Slamon Dennis Director   –       •      –    2024-03-18 4 OE $79.70 $797,000 D/D 10,000 40,809     -
   Burkhart Erin GVP, Chief Accounting Officer   •       –      –    2024-03-18 4 D $83.87 $31,200 D/D (372) 18,442     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2024-03-15 4 D $83.87 $2,808,387 D/D (33,485) 196,872     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2024-03-15 4 A $0.00 $0 D/D 18,240 230,357     -
   Burkhart Erin GVP, Chief Accounting Officer   •       –      –    2024-03-15 4 A $0.00 $0 D/D 4,720 18,814     -
   Hardy Alexander Chief Executive Officer   •       •      –    2024-03-15 4 A $0.00 $0 D/D 32,780 148,151     -
   Davis George Eric EVP, Chief Legal Officer   •       –      –    2024-03-15 4 D $83.87 $1,819,895 D/D (21,699) 80,458     -
   Davis George Eric EVP, Chief Legal Officer   •       –      –    2024-03-15 4 A $0.00 $0 D/D 10,260 102,157     -
   Bienaime Jean Jacques Director   –       •      –    2024-03-15 4 D $83.87 $7,146,479 D/D (85,209) 474,994     -
   Mueller Brian EVP, Chief Financial Officer   •       –      –    2024-03-15 4 D $83.87 $1,743,573 D/D (20,789) 71,859     -
   Mueller Brian EVP, Chief Financial Officer   •       –      –    2024-03-15 4 A $0.00 $0 D/D 11,400 92,648     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2024-03-15 4 D $83.87 $1,893,785 D/D (22,580) 71,467     -
   Guyer Charles Greg EVP, Chief Technical Officer   •       –      –    2024-03-15 4 D $83.87 $1,712,961 D/D (20,424) 78,327     -
   Guyer Charles Greg EVP, Chief Technical Officer   •       –      –    2024-03-15 4 A $0.00 $0 D/D 10,550 98,751     -
   Bienaime Jean Jacques Director   –       •      –    2024-03-06 4 S $86.71 $86,713 D/D (1,000) 560,203     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2024-03-05 4 AS $87.07 $348,280 D/D (4,000) 94,047 3%     
   Fuchs Henry J President, Worldwide R&D   •       –      –    2024-03-05 4 S $85.18 $3,010,396 D/D (35,341) 212,117     -
   Bienaime Jean Jacques Director   –       •      –    2024-03-05 4 S $85.51 $85,510 D/D (1,000) 561,203     -
  2549 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 102
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us